What You Should Know:
Belong.Life, a leading global provider of AI-powered patient education and support solutions, has unveiled the BelongAI Dave - Cancer Mentor app to bring the most advanced and comprehensive cancer support technology to patients and caregivers around the world.The new solution marks a significant step forward in personalized cancer support, by providing patients with a proactive and comprehensive conversational-AI solution for managing their journey
Read More
Oncology Technology Solutions, Services Impacting Patients and Providers
6 Ways AI is Impacting Cancer Diagnosis, Treatment and Patient Outcomes in 2024
Artificial intelligence (AI) technology is set to transform the field of diagnostics, similar to how X-rays and genetic tests revolutionized healthcare in the past. Reshaping routine diagnostic procedures and treatment decisions and propelling pharmaceutical and research domains into new realms, AI offers significant benefits to clinicians, healthcare systems, researchers, and, most importantly, patients. This is particularly evident in cancer diagnosis and treatment across six key areas:
1.
Read More
ConcertAI Acquires CancerLinQ to Expand Real-World Data and AI Solutions for Cancer Care
What You Should Know:
- ConcertAI, a developer of AI-powered healthcare solutions, announced today the acquisition of CancerLinQ, a subsidiary of the American Society of Clinical Oncology (ASCO).
- This strategic move will significantly enhance and expand CancerLinQ's capabilities, unlocking the potential of real-world data and next-generation AI to revolutionize cancer care and accelerate clinical research.
CancerLinQ Background
CancerLinQ represents one of the largest oncology
Read More
Syapse and FDA OCE Collaborate to Advance Real-World Evidence in Oncology
What You Should Know:
- Syapse®, a leading real-world evidence (RWE) company dedicated to extinguishing the fear and burden of serious diseases, and the FDA Oncology Center of Excellence (OCE) today announced the renewal of their four-year collaboration agreement.
- This expanded strategic partnership aims to collaboratively develop and implement research projects that advance the use of real-world data (RWD) and explore the potential of RWE to inform regulatory decisions in
Read More
Absci and AstraZeneca Sign $247M Partnership for AI-Powered Drug Discovery to Fight Cancer
What You Should Know:
- Absci Corporation (ABSI), a pioneer in using generative AI to discover antibodies, and AstraZeneca, a global biopharmaceutical leader, announced a collaboration today to develop an AI-designed antibody for cancer.
- This partnership combines Absci's cutting-edge Integrated Drug Creation™ platform with AstraZeneca's oncology expertise, aiming to accelerate the discovery of a potential new cancer treatment.
Absci's AI Engine Takes the Lead
Absci will leverage
Read More
Guardant Health, Flatiron Health Integrate Genomic Profiling Tests into OncoEMR® Platform
Georgiamune and Verily Partner to Advance Novel Cancer Treatment
What You Should Know:
- Georgiamune, a privately held, clinical stage biotechnology company, and Verily, an Alphabet precision health technology company forms a strategic partnership to advance novel therapeutics for patients with cancer.
- Through this partnership, Verily and Georgimune will focus on identifying the patient population that could potentially benefit the most from Georgiamune’s GIM-122, a first-in-class dual-functioning antibody that has the potential to help patients with
Read More
Penn Medicine Taps Flatiron Health for Advanced Cancer Care
What You Should Know:
Flatiron Health today announced a new agreement to bring Flatiron Assist™ advanced cancer care insights to oncology care clinicians at Penn Medicine’s Abramson Cancer Center (ACC).The collaboration between Flatiron Health and Penn Medicine will focus on further enabling clinicians at ACC to determine and promote site-preferred pathways and open clinical trials at the point of care alongside the NCCN Clinical Practice Guidelines in Oncology (NCCN
Read More
Pangea, FibroFighters Partner to Advance Rare Liver Cancer Treatment
What You Should Know:
Pangea Biomed, the startup behind the innovative treatment response predictor, ENLIGHT, today announced its partnership with patient-centric advocacy organization FibroFighters to advance treatment for fibrolamellar carcinoma (FLC) patients.Fibrolamellar carcinoma (FLC) is a rare liver cancer that typically presents in young adolescents and young adults at a median age of 22 who have no history of liver disease. There is no clear standard of care for the disease, and in
Read More
FDA Selects Ontada to Investigate Rare Cancers Treated in US Community Oncology Setting
What You Should Know:
Ontada, announced it was awarded a competitive contract with the U.S. Food and Drug Administration (FDA) to advance the use of real-world data (RWD) in the U.S. community oncology setting.Ontada will conduct real-world research (RWR) that aims to strengthen the scientific understanding of the natural history of rare cancers by leveraging Ontada’s community oncology footprint and unique RWD.
Study Goals & Objectives
The goal of the study is to
Read More
